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ABSTRACT
Pyogenic streptococci are a major cause of invasive infection. This study presents the results of a
population-based laboratory surveillance for invasive pyogenic streptococcal infections among residents
of the Calgary Health Region (population 1 million) between 1 July 1999 and 30 June 2004. The overall
annual incidence rate was 18.65 ⁄ 100 000 population, with isolates belonging to the Streptococcus milleri
group forming the most important aetiology (incidence of 8.65 ⁄ 100 000 population). Invasive infection
with groups A, B, G and C streptococci occurred at annual rates of 4.27, 3.13, 1.83 and 0.41 ⁄ 100 000
population, respectively. There was a close relationship between increasing age and development of an
invasive pyogenic streptococcal infection, and the incidence of infection was higher among males than
among females. Differences in the seasonal occurrence and focus of infection occurred between the
different groups.
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INTRODUCTION
Pyogenic streptococcal infections, including those
caused by the Streptococcus milleri group (SMG)
and Lancefield groups A, B, C and G streptococci,
have emerged as a major human health concern in
recent decades [1–3]. Several large population-
based surveillance studies have documented rates
of infection with invasive group A streptococci
(GAS) of 2–5 ⁄ 100 000 population annually [1,4–8].
Similarly, while group B streptococci (GBS) were
recognised initially as causing disease affecting
neonates and pregnant women, surveillance
studies have demonstrated that GBS are also an
important cause of invasive infection in men and
non-pregnant women, with overall annual infec-
tion rates of c. 2–9 ⁄ 100 000 [2,9–11]. Although the
epidemiology of invasive GAS and GBS in general
populations is well-defined, this is not the case for
other pyogenic streptococci. While it is recognised
widely that streptococci belonging to groups C
and G (GCGS) are an important cause of pyogenic
infections, few population-based data exist con-
cerning the epidemiology of invasive disease
caused by GCGS [3,12–18]. Similarly, although
numerous case reports and case series document
the propensity of SMG (also known as the
Streptococcus anginosus group, i.e., Streptococcus
constellatus, Streptococcus anginosus and Streptococ-
cus intermedius) to cause abscesses in deep body
sites, only bacteraemia rates have been reported,
and the overall incidence of invasive infections
remains unknown [3,19–23].
Determining the incidence of pyogenic strep-
tococcal infections is important in establishing
healthcare service and research priorities. High-
quality data concerning invasive infection exist
for only some of the pyogenic streptococci, and
a population-based comparative analysis for the
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different organisms within this group is needed.
The objective of the present study was to define
the incidence of and demographic risk-factors
for acquisition of pyogenic streptococcal infec-
tions, and to compare and contrast the epidemi-
ology and foci of infection of the different
streptococcal species in a large Canadian
population.
PATIENTS, MATERIALS AND
METHODS
Study population
The Calgary Health Region (CHR) provides publicly funded
healthcare for a population of > 1 million in the cities of
Calgary and Airdrie and the surrounding area. All residents of
the CHR with identified invasive pyogenic streptococcal
infections between 1 July 1999 and 30 June 2004 were included
in the study. For the purposes of this study, pyogenic
streptococci included GAS, GBS, SMG and GCGS. As GCGS
may include the same species with different Lancefield
grouping, and since speciation was not performed routinely,
a decision was made to treat these organisms as a single group
(GCGS) in this study. Other potentially pus-forming strepto-
cocci were not included. This study underwent institutional
ethics review and approval.
Population-based surveillance
The study used an active, population-based laboratory
surveillance design [24]. All invasive pyogenic streptococcal
infections occurring among CHR residents were identified
by the regional microbiology laboratory (Calgary Laboratory
Services), which performs nearly all (> 95%) routine micro-
biology tests requested by hospitals, nursing homes, physi-
cians’ offices and community collection sites in the CHR.
Pyogenic streptococci were classified as SMG (S. constellatus,
S. intermedius and S. anginosus), GAS (Streptococcus pyogenes),
GBS (Streptococcus agalactiae) or GCGS [23]. As the study
investigators actively identified all cases, passive reporting
by health professionals was not required.
An invasive infection was defined by the isolation of a
pyogenic streptococcus from either a normally sterile
sample (e.g., blood, cerebrospinal fluid, bone or synovial
fluid) or from samples obtained from deep body site
aspirates or intra-operative specimens [25]. In cases where
it was unclear whether infections were invasive (e.g., intra-
abdominal or soft-tissue cultures), they were only deemed to
represent invasive disease following a review of all available
laboratory information, including the sending location, spe-
cimen type, physician specialty, and requisition comments.
Infections were classified either as a primary focus or as
non-focal if there was bacteraemia without evidence of a
primary focus [26]. In brief, an invasive culture from a focal
site (e.g., pleural or synovial fluid) was taken as evidence for
focal infection at that site. For patients whose only invasive
culture was from blood, evidence for a focal infection was
deemed to be present if an isolate belonging to the same
species was obtained from a non-sterile site (e.g., sputum,
urine or wounds) within 2 days of the invasive isolate.
Patients with positive blood cultures alone were classified as
having a non-focal infection. Infections involving the same
organism in a given patient within the same year were
classified as a single incident. Basic laboratory and demo-
graphic data were obtained from the regional laboratory
information system and exported to the main study data-
base. Establishment of regional residency status was per-
formed as described previously [27].
Laboratory procedures
All b-haemolytic and bile-soluble streptococci from normally
sterile sites were speciated routinely using standard proce-
dures. Other a- and non-haemolytic streptococci from all
sterile sites were speciated, but only from blood cultures if
they were present in more than one set of cultures, or
following a physician’s specific request.
Bacterial colonies growing on blood agar plates were
characterised by haemolysis reaction, colony size and a
negative catalase reaction. Microscopy was performed to
identify Gram-positive cocci growing in pairs and chains.
Large-colony b-haemolytic streptococci were typed by their
Lancefield reaction (PathoDx; Oxoid, Ontario, Canada) and
tested for the presence of L-pyroglutamyl-peptide hydrolase
(PYR) by the disk method (PML Identicult; PML Microbiolog-
ics, Mississauga, Canada). PYR-positive Lancefield GAS were
classified as S. pyogenes, while PYR-negative Lancefield GBS
were classified as S. agalactiae. Large-colony b-haemolytic
Lancefield group C or G PYR-negative streptococci were
classified as GCGS [23,28]. Other streptococci, including small-
colony b-haemolytic streptococci isolated from normally sterile
sites, were speciated using optochin sensitivity and PYR,
leucine aminopeptidase (LAP; Dalynn Biologicals, Calgary,
Canada), acetoin production (VP test; Dalynn Biologicals,
Calgary, Canada) and arginine reaction. Isolates that were
PYR-negative and LAP-, VP- and arginine-positive were
classified as SMG.
Before 2001, not all viridans streptococci were tested
routinely using VP, arginine and PYR tests; as a result, many
SMG strains were probably reported as viridans group
streptococci. As a result of this bias for case ascertainment,
data on SMG were only available for the final 3 years of
surveillance, when this was not a concern.
Antimicrobial susceptibility testing was performed using
disk-diffusion methods before October 2002, and subsequently
by a broth microdilution technique (MICroSTREP plus 1 panel;
Dade Behring, Sacramento, CA, USA) according to NCCLS
guidelines [29,30]. Routine testing for inducible lincosamide
resistance was not performed.
Statistical analysis
All analyses were performed using Stata v. 8.0 software (Stata
Corp., College Station, TX, USA). Differences in proportions
among categorical data were assessed using Fisher’s exact test.
Incidence rates were calculated using demographic data
available from the 2001 Canadian National Census specific to
the April 2003 boundaries of the CHR, adjusted for 2% annual
population growth. Differences between incidence rates were
assessed by a comparison of Poisson counts. Specific quarterly
(seasonal) incidence rates (summed quarterly over the 5-year
period of the study) were compared for each of the pyogenic
streptococcal groups only if a significant (p < 0.05) overall
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difference was observed. Age- and gender-specific risks were
calculated and reported as risk ratios with 95% CIs as
described previously [7].
RESULTS
In total, 796 CHR residents were identified with
invasive streptococcal infections. Positive cultures
were submitted from 337 (42%) hospital inpa-
tients, 287 (36%) patients attending emergency
departments, and 172 (22%) patients attending
ambulatory clinics. There were 801 invasive
pyogenic streptococcal infections among the 796
CHR residents; one infection was a second epi-
sode (with 3 years between episodes) and four
patients had two separate episodes with different
invasive streptococcal species. The annual inci-
dence of infection was highest for SMG
(8.65 ⁄ 100 000 population), compared with 4.27,
3.13 and 2.24 ⁄ 100 000 population for GAS, GBS
and GCGS (1.83 for group G and 0.41 for group C
streptococci), respectively. The overall annual
incidence rate for invasive pyogenic streptococcal
infection was 18.65 ⁄ 100 000 population; this did
not vary significantly during the 3-year period for
which data were available (Fig. 1).
The overall occurrence of invasive pyogenic
streptoccocal disease was lowest in summer and
early autumn (Fig. 2). Significant seasonal differ-
ences in incidence were observed according to
group. Invasive SMG infections showed an over-
all significant (p < 0.01) quarterly variation, with
the highest rate of 11.70 ⁄ 100 000 population
during the autumn (October–December), com-
pared with 7.64 ⁄ 100 000 population for the rest of
the year (p < 0.001). Overall, there was significant
quarterly variation for GAS (p < 0.01), which
were isolated at a lower rate in the summer
(July–September) compared with the other three
seasons of the year (2.6 vs. 4.8 ⁄ 100 000 popula-
tion; p < 0.001). In contrast, infections with GCGS
occurred most commonly during spring and
summer (2.8 ⁄ 100 000 population), with the lowest
rates in autumn and winter (1.7 ⁄ 100 000 popula-
tion; p < 0.01). No significant overall seasonal
variation was observed for GBS.
Demographic risk-factors
The median age of the patients was 52 years
(interquartile range, 35–71 years), and 451 (57%)
of the patients were male. There was a close
relationship between increasing age and the risk
for development of an invasive pyogenic
streptococcal infection (Fig. 3). The overall annual
rate of infection was higher in males than females
(21.0 vs. 16.2 ⁄ 100 000 population; risk ratio, 1.30;
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Fig. 1. Annual incidence of invasive pyogenic streptococ-
cal infections in the Calgary Health Region (1 July 1999 - 30
June 2004). SMG, Streptococcus milleri group; GAS, group A
streptococci; GBS, group B streptococci; GCGS, group C
and G streptococci.
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Fig. 2. Seasonal occurrence of invasive pyogenic strepto-
coccal infections in the Calgary Health Region. SMG,
Streptococcus milleri group; GAS, group A streptococci;
GBS, group B streptococci; GCGS, group C and G strep-
tococci.
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Fig. 3. Age- and group-specific incidence of invasive
streptococcal infection in the Calgary Health Region.
SMG, Streptococcus milleri group; GAS, group A strepto-
cocci; GBS, group B streptococci; GCGS, group C and G
streptococci.
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95% CI, 1.11–1.53; p 0.001). The increased risk of
infection among males was seen with each of the
pyogenic streptococci, with the notable exception
of GBS, for which the risk for females did not
differ significantly from that for males (3.2 vs.
3.0 ⁄ 100 000 population; risk ratio, 1.07; 95% CI,
0.78–1.47; p 0.7). The relationship between
increasing age and the development of invasive
pyogenic streptococcal infection was, in part,
associated with the streptococcal group (Fig. 3).
Foci of infection
Of the total of 801 incident infections, 450 (56%)
were focal, with the most common primary foci
being intra-abdominal (132; 16%), soft-tissue (103;
13%) and bone ⁄ joint (96; 12%) infections
(Table 1). There was a significant relationship
between the focus of infection and the strepto-
coccal group, with most SMG infections (235 ⁄ 284;
83%) being focal, compared with 110 ⁄ 229 (48%)
for GAS, 61 ⁄ 168 (36%) for GBS and 44 ⁄ 120 (37%)
for GCGS.
Antimicrobial resistance
Susceptibility data for penicillin, erythromycin
and clindamycin were available for 719 (90%) of
801 isolates. Resistance to penicillin was detected
in only two SMG isolates. Reduced susceptibil-
ity to erythromycin was detected in 94 (13%)
isolates (17 indeterminate and 77 fully resistant),
and to clindamycin in 54 (8%) isolates (17
indeterminate and 37 fully resistant). Among the
four different species ⁄ groups of streptococci, GBS
showed significantly higher rates of resistance to
erythromycin (32 ⁄ 152 (21%) vs. 25 ⁄ 241 (10%)
among SMG isolates, 22 ⁄ 212 (10%) among GAS,
and 15 ⁄ 112 (13%) among GCGS; p < 0.01) and
clindamycin (19 ⁄ 152 (13%) vs. 14 ⁄ 244 (6%)
among SMG isolates, 13 ⁄ 211 (6%) among GAS,
and 8 ⁄ 112 (7%) among GCGS; p 0.01). No
significant relationship between rates of resis-
tance and the time of isolation during the study
were observed.
DISCUSSION
This study detected an overall annual rate for
invasive pyogenic streptococcal infections of
19 ⁄ 100 000 population. This is comparable with
population-based incidence rates reported
for invasive pneumococcal disease in the USA
(20–22 ⁄ 100 000) and invasive Staphylococcus aure-
us disease in the Calgary Health Region
(28 ⁄ 100 000) [31–33]. The annual rates for invasive
disease caused by GAS and GBS of 4.3 and
3.1 ⁄ 100 000 population, respectively, are compar-
able with rates of 1.5–5 and 2–9 ⁄ 100 000
population, respectively, reported from popula-
tion-based studies in the USA, Finland and
Ontario, Canada [1,2,4–7,9]. There are few data
available concerning incidence rates of invasive
infections with GCGS. A population-based study
of group G streptococcal bacteraemia in Northern
Jutland, Denmark reported a rate of 3 ⁄ 100 000
population in the early 1980s, increasing to
17 ⁄ 100 000 population in the late 1990s [16].
Ekelund et al. [18] reported approximate rates
(calculated from the data in the report) in
Denmark of 3 and 0.5 ⁄ 100 000 population annu-
ally for group G and C streptococcal infection,
respectively [18]. A novel and unexpected finding
of the present study was that the incidence rate of
invasive SMG infections was comparable to the
rates of all the other pyogenic streptococcal
aetiologies combined in this region.
The paramount importance of SMG among the
pyogenic streptococci identified in the present
study is not reflected in the published literature.
SMG strains may potentially be under-recognised
as major human pathogens, possibly because
of laboratory identification and reporting proce-
dures. In addition, some authors have classified
SMG infections as non-pyogenic [3]. Most clinical
microbiology laboratories do not fully identify
a-streptococci (other than Streptococcus pneumoni-
ae) or viridans group streptococci, so it is likely
that SMG infections are under-reported. Nucleic
Table 1. Clinical foci of invasive pyogenic streptococcal
diseasea
Focus
SMG
(n = 284)
GAS
(n = 229)
GBS
(n = 168)
GCGS
(n = 120)
Total
(n = 801)
Non-focal 49 (17%) 119 (52%) 107 (64%) 76 (63%) 351 (44%)
Bone ⁄ joint 18 (6%) 34 (15%) 20 (12%) 24 (20%) 96 (12%)
Central nervous
system
11 (4%) 2 (1%) 8 (5%) 1 22 (3%)
Soft-tissue 43 (15%) 44 (19%) 6 (4%) 10 (8%) 103 (13%)
Intra-abdominal 106 (37%) 8 (3%) 16 (10%) 2 (2%) 132 (16%)
Vascular 1 2 (1%) 0 1 (1%) 4 (1%)
Upper respiratory
tract
4 (1%) 7 (3%) 0 1 (1%) 12 (2%)
Lower respiratory
tract
51 (18%) 12 (5%) 4 (2%) 4 (3) 71 (9%)
Urine 1 1 7 (4%) 1 (1%) 10 (1%)
aPercentages refer to proportion of infections caused by each streptococcal group.
SMG, Streptococcus milleri group; GAS, group A streptococci; GBS, group B
streptococci; GCGC, group C and G streptococci.
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acid sequencing is the most accurate method
for speciating SMG isolates, but this technology is
not available routinely in most clinical laborator-
ies [34]. It was only following the implementation
of routine testing of all viridans streptococci by
VP, arginine and PYR reactions that it became
evident that SMG strains were being isolated
frequently.
Although it is possible that the high incidence
of SMG infections is a phenomenon specific to the
CHR, such infections may be common in similar
populations elsewhere. The CHR includes both
urban and rural areas, has 15–20% ethnic minor-
ities, and has an age distribution that is similar to
that of many other North American populations
and developed countries in other continents. The
unusually high rate of SMG disease could be
specific to the CHR. However, given that the rates
for other pyogenic streptococci are comparable
to those in other regions, both nationally and
internationally, it seems that these infections
may be under-recognised, because of inadequate
laboratory identification and ⁄ or because formal
population-based studies have not been con-
ducted elsewhere. Population-based studies in
other regions, nationally and internationally, are
needed to explore this possibility further.
Several epidemiological features were observed
among the pyogenic streptococci. With the excep-
tion of GBS infections, which were stable over the
course of a given year, the other species ⁄groups of
pyogenic streptococci showed seasonal variation
in infection rates (Fig. 2). This was not a surpri-
sing finding, as invasive group A streptococcal
infections have been shown previously to be at a
nadir during the summer months, possibly
because of the reduced prevalence of respiratory
viruses during this period [1]. However, to our
knowledge, seasonal variation of infections with
SMG or GCGS has not been documented previ-
ously. The observation that invasive pyogenic
streptococcal infections occurred more commonly
in males and older patients is similar to previous
findings and may reflect, at least in part, the
differential presence of co-morbid conditions
[1,24,26,31]. Some investigators have suggested
that bacteraemia with GCGS may be a marker for
the presence of an underlying malignancy [13,14],
but no previous study has established and quan-
tified this possibility.
Although the present data were obtained from
a study lasting only 5 years, they do not, with the
exception of GBS, indicate either a rising inci-
dence or a high rate of resistance to antimicrobial
agents among the pyogenic streptococci. While it
is commonly believed that the incidence of pyo-
genic streptococcal infections, particularly those
caused by GAS, may be increasing, the present
data indicated a trend towards a decreased
incidence of invasive group A streptococcal infec-
tions during the past 5 years in the CHR,
although short-term variability can be observed
from year to year, even during periods of stability
[18]. Several studies have reported increased rates
of resistance to penicillin and macrolides among
the pyogenic streptococci. Rates of reduced sus-
ceptibility of c. 5% and 12–15% to penicillin and
erythromycin ⁄ clindamycin, respectively, have
been reported among SMG isolates elsewhere
[21,35]. A large laboratory-based study of bacter-
aemic isolates from the UK reported rates of
resistance to erythromycin of 4%, 7% and 14%
among GAS, GBS and GCGS, respectively [3]. The
present data support the continued use of peni-
cillin, but raise serious concern regarding the use
of erythromycin or clindamycin as empirical
therapy for serious pyogenic streptococcal infec-
tions.
Although a rigorous population-based labora-
tory surveillance design was used, there are some
limitations of this study that merit discussion.
First, while data were complete for the other
streptococci, data for SMG were only available
for the latter 3 years of the study. Second,
detailed clinical information concerning true
invasiveness and focus was not available for all
infections. While invasiveness was not an issue
for the vast majority of cases with positive
cultures from blood, cerebrospinal fluid, synovial
aspirates and surgical tissues, some judgement
was required for occasional specimens, e.g., fluids
obtained from intra-abdominal sites. However,
< 10% of the cases in this study involved such
samples, so only a small degree of bias would
result. Since the focus of infection was based on
microbiological criteria, it is likely that some truly
focal infections were misclassified as non-focal,
with a resulting over-estimate of the number of
cases of primary bacteraemia. Third, as with all
studies that utilise similar designs, only infections
for which adequate cultures were performed were
detected by surveillance, and the true rate is
likely to be higher than that observed. Fourth,
no information was available as to whether
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infections were community- or hospital-acquired.
Fifth, group C and G streptococci were pooled as
a single group for analysis, so the data are not
readily comparable with those from studies that
investigated these groups separately. However,
there is difficulty in ascribing a speciation based
on Lancefield groups C and G alone. Finally, no
information was available regarding other
important clinical data, such as the need for
hospital admission, length of stay, need for
management in an intensive care unit, surgical
procedures, antimicrobial therapy and mortality
outcome. While these data are important, and will
form the basis for future investigations, the
present study is a critical first step in elucidating
the burden of invasive pyogenic streptococcal
infections.
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